ASH 2013: Dr Jeff Sharman Discusses the Ideal ... - CLL Support

CLL Support

22,512 members38,666 posts

ASH 2013: Dr Jeff Sharman Discusses the Ideal Design of Phase 3 Trials with Novel Agent versus the Reality in the Community

bkoffman profile image
bkoffmanCLL CURE Hero
2 Replies

Hi friends,

I just posted on my blog bkoffman.blogspot.com an interesting interview with the very lucid Dr. Sharman on the trials of clinical trial design.

This is important for anyone who is considerign enterign a clinical trial

Let me know what you think

Thanks

Brian

Written by
bkoffman profile image
bkoffman
CLL CURE Hero
To view profiles and participate in discussions please or .
Read more about...
2 Replies

Thanks for this Brian, my initial reaction was that it seemed unfair that the better option was not being offered to 50 per cent of those on the trial. I was molified somewhat at the crossover option, but still wonder whether there is a yet unmentioned drug that has passed initial trials that could be used in such a trial.

Guess phase 3 is more of a proving trial.. If so perhaps we can look forward to a reasonably early release.

Bubnjay

bkoffman profile image
bkoffmanCLL CURE Hero

Should be approved this year in the USA if all goes well

You may also like...

iwCLL 2013: Dr. Sharman discusses why we feel so lousy, and much more.

go on from there. Please seem my blog: http://bkoffman.blogspot.com Parts 5-7 will follow in...

AVO clinical trial for CLL

Just started the AVO (Acalabrutinib, Venetoclax, Obinutuzmab, clinical trial at Dana Farber just...

Early treatment for high risk CLL

Is recommended by this randomized controlled clinical trial....

Richter’s Transformation - Preliminary results of the clinical trial with Mosunetuzumab

Preliminary results of the clinical trial with clinical Mosunetuzumab at the ASH2019 congress. The...

Clinical Trials studying COVID-19 vaccines in CLL: Some have begun/ others are coming!

Clinical Trials studying COVID-19 vaccines in CLL: In response to all those who have reached out to...